Future oncology (London, England) · 2025
Advancing real-world research in thoracic malignancies: learnings from the international I-O Optimise initiative.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Johnsen Søren Paaske, Baas Paul, Sørensen Jens Benn, Chouaid Christos, Griesinger Frank, Daumont Melinda J, Rault Caroline, Emanuel Gabrielle, Penrod John R, Jacobs Hazel, Muwaffak Maha, Schoemaker Minouk J, Munro Robin Ej, Baskaran Darshan, Durand-Zaleski Isabelle, O'Donnell John C
Аннотация
In recent years, the thoracic malignancies treatment landscape has become more complex with the emergence of novel targeted and immunotherapy-based treatments. Although beneficial to patients and physicians, this fast-paced therapeutic evolution has increased the complexity of clinical decision-making and amplified the importance of real-world evidence to support data from randomized controlled trials. The international I-O Optimise initiative was established in 2016 to provide real-world insights into the thoracic malignancies treatment landscape, and has since collaborated with 14 data sources across Europe and Canada, allowing access to data from ~ 500,000 patients with non-small-cell lung cancer, small-cell lung cancer, and malignant pleural mesothelioma. This article reviews pertinent I-O Optimise research, with discussion of the methodological/data-related learnings and expectations for future insights.